Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242446 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 505
- Enrollment target
- 20
- Study locations
NCT04242446 is a Phase 3 study of Hidradenitis Suppurativa that has completed, run by UCB Biopharma SRL. The registered enrollment target is 505 participants, below the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04242446, a Phase 3 study of Hidradenitis Suppurativa, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 505 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bimekizumab
Study Locations (20)
Florida
- Hs0003 50205 - North Miami Beach
- Hs0003 50153 - Ormond Beach
- Hs0003 50141 - Tampa
California
- Hs0003 50161 - Los Angeles
- Hs0003 50220 - San Diego
Georgia
- Hs0003 50210 - Atlanta
- Hs0003 50280 - Watkinsville
Massachusetts
- Hs0003 50198 - Beverly
- Hs0003 50146 - Boston
Ohio
- Hs0003 50177 - Cincinnati
- Hs0003 50138 - Columbus
Alabama
- Hs0003 50140 - Birmingham
Arizona
- Hs0003 50175 - Phoenix
Kentucky
- Hs0003 50425 - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2023-02-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242446
The ClinicalTrials.gov registry entry for NCT04242446 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (14% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04242446 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04242446 about?
NCT04242446 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa". The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
What is the current status of trial NCT04242446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 505 participants. The study started on 2020-02-19. Estimated completion is 2023-02-19.
What conditions does trial NCT04242446 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT04242446?
The interventions under investigation include: Placebo (OTHER), Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04242446?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04242446 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.